# 🩸 Rethinking "Fistula First"

## 🎯 The Big Picture

For decades we told every hemodialysis patient the same thing: **get a fistula.** That instruction was built entirely on **observational data** — no randomized trial ever proved a fistula saves lives compared with a catheter.

The uncomfortable truth: much of the fistula's apparent survival advantage is **the healthier patient, not the access.** Sicker patients with poor vessels and short survival end up on catheters — so comparing catheter patients to fistula patients partly compares sick people to well people and credits a piece of hardware.

### ✅ Where the Fistula Still Wins

- The **robust older patient** with good vessels and a long horizon
- Back-loaded benefits (low infection, good patency) are real *if the patient lives to collect them*

### ⚠️ Where Reflexive "Fistula First" Fails

- The **frail, catheter-dependent older starter** with high competing mortality
- A short time horizon means the patient may never reach the payoff

### 💡 The Reframing That Runs the Whole Lecture

The question is never "fistula or catheter?" in the abstract. It is: **does *this* patient live long enough, with vessels good enough, to convert the front-loaded cost of a fistula into a back-loaded benefit?**

## 🩸 The Three Options

Three access types exist, each with an honest trade-off. For a fit 50-year-old with good veins, the fistula is close to unarguable. The calculus bends once the patient is 75, frail, multimorbid, and already dialyzing through a catheter.

| Feature | Fistula (AVF) | Graft (AVG) | Tunneled Catheter (CVC) |
|----|----|----|----|
| **Time to use** | Months (median approximately 115 days) | Weeks (early-cannulation grafts sooner) | Immediate |
| **Maturation failure** | High, especially in older patients | Lower — grafts "mature" reliably | N/A |
| **Infection risk** | Lowest once working | Intermediate | Highest |
| **Maintenance** | Good patency, but frequent upkeep | Frequent thrombosis / reintervention | Dysfunction, tPA, exchange |
| **Best-fit patient** | Long survival, good vessels | Needs permanent access but poor veins / faster timeline | Short horizon, bridging, strong preference, exhausted sites |

### 🧪 A Fistula Is a Program, Not a One-Time Procedure

The NIH Hemodialysis Fistula Maturation Study found unassisted maturation of only **29% at 3 months, 67% at 6 months, and 76% at 12 months** (median 115 days). Over one-third needed a procedure just to mature, and **47.5% of matured fistulas needed further intervention** to stay open. A fistula is not "place it and forget it" — it is a schedule of procedures.

## 🧩 Why "Fistula First" Is Weaker Than It Looks

The observational survival gap is real and large — a systematic review of 62 cohort studies (586,337 patients) found catheters carried roughly **1.5× the mortality** of fistulas. But the authors themselves graded the underlying studies as **high risk of bias, especially selection bias.** The association is real; the *causal* reading is where it breaks. Three studies dismantle it.

### 🔬 Brown 2017 — the smoking gun

In 115,425 Medicare patients aged 67+, the group that **attempted a fistula, had it fail, and dialyzed through a catheter anyway** still beat catheter-first patients (HR 0.66). If a failed fistula still helps, the benefit cannot live in the fistula. Authors: **approximately two-thirds patient factors, one-third access.**

### ⚰️ Quinn 2017 — cause of death

Every death in 2,300 patients was independently adjudicated. If catheters killed via line sepsis, access-related deaths should be common. They weren't — only **approximately 2% of deaths were access-related.** The excess catheter mortality "does not appear to be due to direct, access-related complications."

### 📐 Lyu 2021 — instrumental variable

Using a target-trial-emulation design that addresses *unmeasured* confounding, the instrumental-variable analysis found **no association** between creating a fistula versus a graft and mortality, sepsis, or hospitalization in elderly patients who all started hemodialysis on a catheter. It did not compare fistula versus staying on a catheter.

### ⚠️ The Confounding Tell

When a "failed fistula attempt" group that dialyzes through a catheter **still beats the catheter-first group**, the benefit cannot be living in the fistula. It is living in whatever made those patients candidates in the first place — good vessels, longer survival, fewer comorbidities. That is the single most useful mental model to carry into an access conversation.

## ⚖️ ACCESS HD — The Trial That Couldn't Recruit

Everything above is observational. The obvious fix is a randomized trial — and that is exactly what **ACCESS HD** attempted (12 centers, Canada + Australia, 2014–2021): older catheter-dependent starters randomized to a **fistula strategy** versus **continued catheter strategy.**

### 🔑 The Primary Endpoint Was Feasibility — Not a Clinical Outcome

This is the key to reading the whole trial. Of 268 eligible patients, **201 declined** and only 67 were randomized. Among those who said no, **37% preferred to keep their catheter** (only 23% preferred a fistula). Patient preference — not surgical capacity — was the dominant barrier to running the trial at all.

The clinical secondaries (n=67, underpowered, no multiplicity adjustment) **mostly favored the catheter arm**: fewer procedures, fewer hospital days, less bacteremia, numerically fewer deaths — and the only adjudicated access-related death occurred in the *fistula* arm. The one outcome favoring the fistula was tPA use, because catheters clot.

### ✅ What ACCESS HD Proves

Two solid things: (1) a definitive fistula-vs-catheter RCT is **not feasible** today, blocked by structural incentives and patient preference; and (2) there is **no signal of harm** from a catheter strategy in older starters — in units whose catheter infection rate was about one-ninth the US national rate, so the lower bacteremia in the catheter arm depends on catheter-care quality.

### 🚫 What It Does NOT Prove

With only 67 patients and no multiplicity adjustment, it **cannot establish that catheters are superior** — and it does not claim to. The clinical signals are hypothesis-generating, not a mandate.

### 💡 Why the Fistula Arm Still Had Line Infections

Patients randomized to a fistula strategy **still had catheters during maturation.** You do not escape the catheter by attempting a fistula — you often add a surgery on top of it and keep the line until (and if) the fistula works. That is why the fistula arm's bacteremia was predominantly catheter-related.

## 👤 The Patient-Centered Framework: The ESKD Life-Plan

The 2019 KDOQI guideline retired the rigid slogan and replaced it with the **End-Stage Kidney Disease (ESKD) Life-Plan** and the principle of **"the right access, in the right patient, at the right time, for the right reasons."** The decision rests on three questions:

### 1️⃣ Survival & Trajectory

A robust patient with years ahead earns the fistula's back-loaded benefit. A frail patient with a short horizon may never reach it.

### 2️⃣ Vessels & Timeline

Poor veins push toward a graft. An urgent need with no mature option may mean a bridging catheter regardless.

### 3️⃣ Patient Preference

ACCESS HD showed this is not a footnote — it is often the deciding factor. More than a third of eligible older patients preferred their catheter.

Older patient starting HD on a catheter ↓ What is the expected survival and trajectory? Short horizon / frail / high competing mortality ↓ **Catheter strategy is reasonable**\
Honor preference; avoid futile surgery Years of expected survival, robust ↓ Are the vessels adequate for a fistula? ↓ **Yes — good targets**\
Fistula: accept the maturation program + reinterventions **Poor veins / faster timeline**\
Graft: reliable maturation, more thrombosis ↓ Overlay patient preference → document the shared decision in the ESKD Life-Plan

### 💡 Don't Forget the Heart

In an older patient with reduced ejection fraction or pulmonary hypertension, a high-flow upper-arm fistula can worsen **high-output physiology.** In that patient the "gold standard" access can be the wrong one on hemodynamic grounds alone — one more reason the hierarchy has to yield to the individual.

## 🔑 Key Takeaways

1.  **Abandon reflexive Fistula-First** for the frail, older, catheter-dependent starter — the randomized data do not support it.
2.  The fistula survival benefit is roughly **two-thirds patient, one-third access**, and access-related complications cause only about 2% of deaths.
3.  **ACCESS HD** shows a definitive trial is not feasible and finds **no harm** from a catheter strategy — but cannot prove catheters are superior.
4.  **Still favor a fistula** in the robust older patient with good vessels and a long horizon; the back-loaded benefits are real if the patient lives to collect them.
5.  A **graft is a legitimate middle path** when veins are poor or the timeline is short.
6.  Anchor every decision in the **ESKD Life-Plan and shared decision-making**. "Right access, right patient, right time, right reason."

[**🎓 Physician-Level Mastery Review →**\
Full PMID-anchored deep dive: the confounding data, ACCESS HD in detail, critical appraisal.](https://urinenephrology.org/mastery/dialysis-advanced/vascular-access-older-patients.html) [**📄 Student Handout →**\
One-page take-home summary for PA students.](https://urinenephrology.org/student-resources/dialysis/vascular-access-selection-student-handout.html)

## 📚 Key References

1.  Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. *J Am Soc Nephrol.* 1996;7(4):523–535. [PMID: 8724885](https://pubmed.ncbi.nlm.nih.gov/8724885/)
2.  Bello AK, Okpechi IG, Osman MA, et al. Epidemiology of haemodialysis outcomes. *Nat Rev Nephrol.* 2022;18(6):378–395. [PMID: 35194215](https://pubmed.ncbi.nlm.nih.gov/35194215/)
3.  Ravani P, Palmer SC, Oliver MJ, et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. *J Am Soc Nephrol.* 2013;24(3):465–473. [PMID: 23431075](https://pubmed.ncbi.nlm.nih.gov/23431075/)
4.  Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. *Am J Kidney Dis.* 2020;75(4 Suppl 2):S1–S164. [PMID: 32778223](https://pubmed.ncbi.nlm.nih.gov/32778223/)
5.  Brown RS, Patibandla BK, Goldfarb-Rumyantzev AS. The Survival Benefit of "Fistula First, Catheter Last" in Hemodialysis Is Primarily Due to Patient Factors. *J Am Soc Nephrol.* 2017;28(2):645–652. [PMID: 27605542](https://pubmed.ncbi.nlm.nih.gov/27605542/)
6.  Quinn RR, Oliver MJ, Devoe D, et al. The Effect of Predialysis Fistula Attempt on Risk of All-Cause and Access-Related Death. *J Am Soc Nephrol.* 2017;28(2):613–620. [PMID: 28143967](https://pubmed.ncbi.nlm.nih.gov/28143967/)
7.  Lyu B, Chan MR, Yevzlin AS, Gardezi A, Astor BC. Arteriovenous Access Type and Risk of Mortality, Hospitalization, and Sepsis Among Elderly Hemodialysis Patients: A Target Trial Emulation Approach. *Am J Kidney Dis.* 2022;79(1):69–78. [PMID: 34118301](https://pubmed.ncbi.nlm.nih.gov/34118301/)
8.  Quinn RR, Ravani P. Fistula-first and catheter-last: fading certainties and growing doubts. *Nephrol Dial Transplant.* 2014;29(4):727–730. [PMID: 24327565](https://pubmed.ncbi.nlm.nih.gov/24327565/)
9.  Quinn RR, Oliver MJ, Wald R, et al. Comparing Catheters with Fistulas in Older Patients Starting Hemodialysis: A Pilot Randomized Controlled Trial. J Am Soc Nephrol. 2026;. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42319856/)
10. Huber TS, Berceli SA, Scali ST, et al. Arteriovenous Fistula Maturation, Functional Patency, and Intervention Rates (HFM Study). *JAMA Surg.* 2021;156(12):1111–1118. [PMID: 34550312](https://pubmed.ncbi.nlm.nih.gov/34550312/)
11. Aitken E, Thomson P, Bainbridge L, et al. A randomized controlled trial and cost-effectiveness analysis of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis. *J Vasc Surg.* 2017;65(3):766–774. [PMID: 28236919](https://pubmed.ncbi.nlm.nih.gov/28236919/)
12. Murea M, Gardezi AI, Goldman MP, et al. Study protocol of a randomized controlled trial of fistula vs. graft arteriovenous vascular access in older adults with ESKD on hemodialysis: the AV Access Trial. *BMC Nephrol.* 2023;24(1). [PMID: 36829135](https://pubmed.ncbi.nlm.nih.gov/36829135/)
13. Nguyen DB, Shugart A, Lines C, et al. National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014. *Clin J Am Soc Nephrol.* 2017;12(7):1139–1146. [PMID: 28663227](https://pubmed.ncbi.nlm.nih.gov/28663227/)

References are reference-verified against source PDFs. ACCESS HD (ref 9) is published ahead of print and not yet PubMed-indexed. [Read the full physician-level review →](https://urinenephrology.org/mastery/dialysis-advanced/vascular-access-older-patients.html)

📚 For Educational Purposes Only

© 2026 Andrew Bland, MD, FACP, FAAP - All Rights Reserved

### Also on this topic

The same subject at other levels of depth.

- **Clinical Mastery deep dive:** [Vascular Access Selection in Older Patients Starting Hemodialysis](https://urinenephrology.org/mastery/dialysis-advanced/vascular-access-older-patients.html)
- **Student handout:** [Vascular Access Selection in Older Hemodialysis Patients: Rethinking "Fistula First"](https://urinenephrology.org/student-resources/dialysis/vascular-access-selection-student-handout.html)


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/dialysis/vascular-access-selection.html) · Markdown synchronized October 3, 2026.